Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Anika Therapeutics (ANIK)

Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,269
  • Shares Outstanding, K 14,850
  • Annual Sales, $ 166,660 K
  • Annual Income, $ -82,670 K
  • 60-Month Beta 0.75
  • Price/Sales 2.26
  • Price/Cash Flow 5.10
  • Price/Book 1.73
Trade ANIK with:

Options Overview Details

View History
  • Implied Volatility 48.21% ( +8.19%)
  • Historical Volatility 31.86%
  • IV Percentile 56%
  • IV Rank 32.78%
  • IV High 81.15% on 04/14/23
  • IV Low 32.14% on 11/28/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 609
  • Open Int (30-Day) 595

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.13
  • Number of Estimates 1
  • High Estimate 0.13
  • Low Estimate 0.13
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +136.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.00 +20.95%
on 03/14/24
27.31 -6.99%
on 03/06/24
+0.63 (+2.54%)
since 02/28/24
3-Month
21.00 +20.95%
on 03/14/24
27.31 -6.99%
on 03/06/24
+2.76 (+12.19%)
since 12/28/23
52-Week
16.54 +53.57%
on 09/08/23
29.25 -13.18%
on 04/03/23
-2.72 (-9.67%)
since 03/28/23

Most Recent Stories

More News
Anika: Q4 Earnings Snapshot

Anika: Q4 Earnings Snapshot

ANIK : 25.40 (-0.55%)
Anika: Q3 Earnings Snapshot

Anika: Q3 Earnings Snapshot

ANIK : 25.40 (-0.55%)
Anika: Q2 Earnings Snapshot

Anika: Q2 Earnings Snapshot

ANIK : 25.40 (-0.55%)
Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of -97.22% and 2.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ANIK : 25.40 (-0.55%)
DNA : 1.1600 (+5.45%)
Anika: Q1 Earnings Snapshot

Anika: Q1 Earnings Snapshot

ANIK : 25.40 (-0.55%)
Anika Therapeutics (ANIK) Stock Sinks As Market Gains: What You Should Know

Anika Therapeutics (ANIK) closed at $26.62 in the latest trading session, marking a -0.89% move from the prior day.

ANIK : 25.40 (-0.55%)
Squarespace, WW International rise; Thor, Anika fall

Stocks that traded heavily or had substantial price changes Tuesday: Squarespace, WW International rise; Thor, Anika fall

QUOT : 3.99 (unch)
CVGI : 6.43 (+0.16%)
OCUL : 9.10 (-2.26%)
DKS : 224.86 (+1.02%)
THO : 117.34 (+2.36%)
ANIK : 25.40 (-0.55%)
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANIK : 25.40 (-0.55%)
AFMD : 5.30 (-0.56%)
Anika: Q4 Earnings Snapshot

Anika: Q4 Earnings Snapshot

ANIK : 25.40 (-0.55%)
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

INO : 13.88 (+6.52%)
ANIK : 25.40 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative...

See More

Key Turning Points

3rd Resistance Point 25.99
2nd Resistance Point 25.80
1st Resistance Point 25.60
Last Price 25.40
1st Support Level 25.22
2nd Support Level 25.03
3rd Support Level 24.83

See More

52-Week High 29.25
Last Price 25.40
Fibonacci 61.8% 24.40
Fibonacci 50% 22.90
Fibonacci 38.2% 21.40
52-Week Low 16.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar